Image source: Getty Images.
Shares of the medical device company DexCom (NASDAQ: DXCM) gained as much as 31% today as of 2:30 p.m. EST. The stock’s surge higher was fueled by the Centers for Medicare and Medicaid Services (CMS) defining continuous glucose monitors (CGM) as “therapeutic” under Medicare Part B. This favorable ruling qualifies the company’s G5 mobile CGM system for coverage under Medicaid and Medicare.